FDA Drug Recalls

Recalls / Class II

Class IID-0385-2023

Product

Dofetilide Capsules 500 mcg (0.5 mg), 60-count bottle, Rx only, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA NDC 16729-492-12 UPC 3 16729 49212 6

Brand name
Dofetilide
Generic name
Dofetilide
Active ingredient
Dofetilide
Route
Oral
NDCs
16729-490, 16729-491, 16729-492
FDA application
ANDA213338
Affected lot / code info
Batches: P2101582, P2101661, P2101482, P2101686, Exp. Date 2/28/2023; P2102581, P2102598, Exp. Date 4/30/2023; P2103623, P2103653, P2103670, Exp. Date 5/31/2023; P2104463, P2104385, P2104386, P2104472, P2104709, P2104714, Exp. Date 6/30/2023; P2200797, P2200773, P2200831, Exp. Date 12/31/2023; P2201017, P2201081, P2201056, Exp. Date 1/31/2024; P2200819, Exp. Date 12/31/2024; P2202611, P2202616, Exp. Date 4/30/2025, P2203467, Exp. Date 5/31/2025

Why it was recalled

CGMP Deviations: recalling drug products following an FDA inspection.

Recalling firm

Firm
Accord Healthcare, Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
1009 Slater Rd Ste 210B, N/A, Durham, North Carolina 27703-8446

Distribution

Quantity
113,003 bottles
Distribution pattern
United States including Puerto Rico and Canada

Timeline

Recall initiated
2023-02-07
FDA classified
2023-03-02
Posted by FDA
2023-03-08
Terminated
2024-04-22
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0385-2023. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Dofetilide · FDA Drug Recalls